Silver Sulfadiazine

WAYNE, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit led by Chuck Gartner, Director of Marketing - Strategic Initiatives. The Teleflex Center for Antimicrobial Protection, located in Research Triangle, North Carolina, is dedicated to reducing the spread of infections caused by multidrug-resistant organisms. Too often patients are exposed to these “superbugs” which can lead to additional complications and an increased length of stay in a hospital setting.1 Through education and partnership with professionals in infection prevention, TCAP seeks to be a resource for patients, physicians, and healthcare organizations. “Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients by helping to reduce vascular access related complications,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular. “We are proud of TCAP’s commitment to antimicrobial catheter technology and our ability to reduce the colonization of major pathogens linked to central line associated blood stream infections (CLABSI).”2 The Teleflex Center for Antimicrobial Protection aims to provide quality products, services, and education to its customers by pioneering catheter protection technology and developing innovative vascular access devices. TCAP recently sponsored an educational webinar focused on the expansion of surveillance of healthcare-acquired infections (HAI), specifically central line-associated bloodstream infections (CLABSI). That webinar can be viewed on-demand through Teleflex Academy. Teleflex, through its Arrow™ Brand of Vascular Access Products, has the only comprehensive portfolio of antimicrobial Chlorhexidine catheters designed to provide broad-spectrum protection against gram-positive, gram-negative, and fungal pathogens.2,3,4 Additionally, Arrow™ Maximal Barrier Kitting options provide protection for patients and improve procedural efficiency for clinicians.5 This portfolio of products was showcased at the Association for Professionals in Infection Control and Epidemiology (APIC) 2024 Annual Conference. During the conference, TCAP sponsored an educational Exhibitor Theater session, focused on CLABSI trends. To learn more about Arrow™ Antimicrobial Catheter and Kitting Solutions, visit our website. About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com. Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue, Arrowg+ard Blue Advance, Arrowg+ard Blue Plus, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks or registered trademarks of their respective owners. © 2024 Teleflex Incorporated. All rights reserved. MC-009780 References: Toor H, Farr S, Savla P, Kashyap S, Wang S, Miulli DE. Prevalence of central line-associated bloodstream infections (CLABSI) in intensive care and medical-surgical units. Cureus. 2022;14(3):e22809.doi:10.7759/cureus.22809In vitro data on file 2010: AVER-004371 and AVER-004483. No correlation between in vitro/in vivo testing methods and clinical outcomes has currently been ascertained.Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of Central Venous Catheter-Related Bloodstream Infection With an 'Antiseptic-Impregnated Catheter: A Randomized, Controlled Trial. Annals of Internal Medicine, August 15, 1997, Vol. 127, Issue 4, pp. 257–266.Spangler D and Moss S. In-Vitro Assessment of Antimicrobial Activity of Three Commercially Available Central Venous Catheters. Poster by Arrow (Teleflex) International, Inc. Department of Applied Research. 2010-0406 v1Fenik Y, Celebi N, Wagner R, et al. Prepackaged central line kits reduce procedural mistakes during central line insertion: a randomized controlled prospective trial. BMC Medical Education. 2013;13:60. Published 2013 Apr 30. doi:10.1186/1472-6920-13-60. https://www-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/pmc/articles/PMC3645964/ Rx only Contraindications: The Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ Catheters are contraindicated for patients with known hypersensitivity to chlorhexidine, silver sulfadiazine and/or sulfa drugs. Clinical assessment of the patient must be completed to ensure no contraindications exist. The Arrowg+ard Blue Advance™ Catheters are contraindicated in the following areas: • Patients with known hypersensitivity to chlorhexidine• In presence of device related infections• In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained. For complete indications, contraindications, warnings, precautions, and adverse reactions, please refer to each referenced product's full package insert. Contacts:TeleflexLawrence KeuschVice President, Investor Relations and Strategy Developmentinvestor.relations@teleflex.com610-948-2836

WAYNE, Pa., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the release of the Arrow™ ErgoPack™ Complete Kits with Hemodialysis and Large Bore catheters in the United States. This update is intended to streamline insertion workflow for clinicians and provide more options to suit their needs. Clinicians can choose between Arrowg+ard Blue™ Hemodialysis or Large Bore lines in this expanded kit configuration, with a variety of French sizes, lumens, and lengths. Learn more about the Arrow™ ErgoPack™ Complete System. The Arrow™ ErgoPack™ Complete System expansion includes a variety of clinician-inspired updates: The Arrow™ GlideWheel™ Advancer, which provides tactile feedback and finer controlNitinol Guidewire, which is kink-resistant compared to stainless steelTransducer Cover to support guidelines for ultrasound usePre-filled sterile saline syringes, one per catheter lumenExtra ChloraPrep® Skin Prep in each kitOption of 3M™ Tegaderm™ CHG I.V. Securement Dressing or 3M™ Tegaderm™ I.V. Advanced Securement Dressing with BioPatch® Protective Disk “Max barrier kits like the Arrow™ ErgoPack™ Complete System provide clinicians with the necessary components they need for their Acute Hemodialysis and Large Bore insertions. The intuitive configuration is designed to optimize their workflow, while also meeting the recommendations of CDC, SHEA, INS, and OSHA guidelines.1-4 Coupling these benefits along with the protection from Arrowg+ard Blue™ Catheters helps clinicians fight against central line-associated bloodstream infections, protecting their patients and improving their procedures.” – said Lisa Kudlacz, President and General Manager, Vascular Access at Teleflex. The Arrow™ ErgoPack™ Complete System’s unique combination of CVC insertion components is packaged in an ergonomic and efficient top down, left to right configuration, and helps central line inserters meet the recommendations of critical third-party independent guidelines for reducing CLABSI, including: Centers for Disease Control and Prevention (CDC) Category 1A & 1B recommendations1Society for Hospital Epidemiology of America (SHEA) Guidelines2Infusion Nursing Society (INS) Standards of Practice3Occupational Health and Safety Administration (OSHA) Bloodborne Pathogens Standard4 About Teleflex IncorporatedTeleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com. Teleflex is the home of Arrow™, Deknatel™, LMA™, Pilling™, QuikClot™, Rusch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. References: O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011 (Revised 2017). 2. Atlanta, GA: Centers for Disease Control and Prevention; 2017.Buetti, N., Marschall, J., Drees, M., Fakih, M., Hadaway, L., Maragakis, L., Mermel, L. (2022). Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update. Infection Control & Hospital Epidemiology, 1-17. doi:10.1017/ice.2022.87.Gorski, Lisa A., et al. "Infusion therapy standards of practice." Journal of Infusion Nursing, 44.1S (2021): S1-S224.Occupational Safety & Health Administration Regulations (Standards – 29 CFR). Part 1910.1030: Bloodborne pathogens. Occupational Safety & Health Administration Web site. https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030. Accessed on February 12, 2020. Rx Only Contraindication:Arrowg+ard Blue™ Acute Hemodialysis and Large Bore Catheters are contraindicated for patients with known hypersensitivity to chlorhexidine and silver sulfadiazine and/or sulfa drugs. 3M and Tegaderm are registered trademarks of 3M or its affiliates. BioPatch is a registered trademark of Johnson & Johnson or its affiliates. ChloraPrep is a registered trademark of Becton, Dickinson and Company or its affiliates. Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue, Deknatel, ErgoPack, GlideWheel, LMA, Pilling, QuikClot, Rusch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other marks are the property of their respective owners.© 2023 Teleflex Incorporated. All rights reserved. MC-008913 Contact:Teleflex Incorporated:Lawrence KeuschVice President, Investor Relations and Strategy Development investors.teleflex.com 610-948-2836